

PI4747USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patentee: Alvaro et al.**Patent No.:** 7,189,713**Issued:** March 13, 2007**Serial No.:** 10/502,255**For:** Piperidine DerivativesREQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed please find a certificate of correction in connection with the above-identified patent. It is respectfully requested that a Certificate of Correction be issued for the above-identified patent, in accordance with 37 C.F.R. § 1.322.

The mistakes appearing in the patent are set forth on the Certificate of Correction enclosed herewith, with an additional copy thereof.

Please charge any shortage in the fees or credit any overpayment to Deposit Account No. 07-1392.

Respectfully submitted,



Lorie Ann Morgan
Registration No. 38,181
Attorney for Patentee

Dated: 13 Jan 2007
GlaxoSmithKline
Corporate Intellectual Property Dept.
Five Moore Drive, PO Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8222
Facsimile: (919) 483-7988

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 7,189,713

Page 1 of 2

APPLICATION NO. : 10/502,255

ISSUE DATE : March 13, 2007

INVENTOR(S) : Alvaro et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 57, claim 10, line 13 should read:

-- dro-pyrrolo[1,2-a]pyrazin-2yl)-piperidine-1-car --

Column 57, claim 14, line 41 should read:

-- CH, A is C(O), X is CH₂, R is independently a halogen or --

Column 57, claim 17, line 53 should read:

-- 2-(R)-(4-Fluoro-2-methyl-phenyl)-4-(S)-((8aS-6-oxo- --

MAILING ADDRESS OF SENDER (Please do not use customer number)

GlaxoSmithKline
Corporate Intellectual Property Department
5 Moore Drive
Research Triangle Park, NC 27709

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 7,189,713

Page 2 of 2

APPLICATION NO. : 10/502,255

ISSUE DATE : March 13, 2007

INVENTOR(S) : Alvaro et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 57, claim 19, line 64 should read:

-- from fluoxetine, citalopram, femoxetine, fluvoxamine, --

Column 58, claim 26, line 33 should read:

-- schizoaffective disorder of the depressed type --

Column 60, claim 61, line 50 should read:

-- [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]- --

Column 62, claim 71, line 36 should read:

-- carboxylic acid[1-(R)-(3,5-bis-trifluoromethyl-phenyl)- --

MAILING ADDRESS OF SENDER (Please do not use customer number)

GlaxoSmithKline
Corporate Intellectual Property Department
5 Moore Drive
Research Triangle Park, NC 27709

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.